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ABSTRACT
Objectives: To examine: (1) changes in polypharmacy
in 1997, 2002, 2007 and 2012 and; (2) changes in
potentially inappropriate prescribing (PIP) prevalence
and the relationship between PIP and polypharmacy in
individuals aged ≥65 years over this period in Ireland.
Methods: This repeated cross-sectional study using
pharmacy claims data included all individuals eligible
for the General Medical Services scheme in the former
Eastern Health Board region of Ireland in 1997, 2002,
2007 and 2012 (range 338 025–539 752 individuals).
Outcomes evaluated were prevalence of polypharmacy
(being prescribed ≥5 regular medicines) and excessive
polypharmacy (≥10 regular medicines) in all
individuals and PIP prevalence in those aged
≥65 years determined by 30 criteria from the
Screening Tool for Older Persons’ Prescriptions.
Results: The prevalence of polypharmacy increased
from 1997 to 2012, particularly among older
individuals (from 17.8% to 60.4% in those aged
≥65 years). The adjusted incident rate ratio for
polypharmacy in 2012 compared to 1997 was 4.16
(95% CI 3.23 to 5.36), and for excessive polypharmacy
it was 10.53 (8.58 to 12.91). Prevalence of PIP rose
from 32.6% in 1997 to 37.3% in 2012. High-dose
aspirin and digoxin prescribing decreased over time,
but long-term proton pump inhibitors at maximal dose
increased substantially (from 0.8% to 23.8%). The
odds of having any PIP in 2012 were lower compared
to 1997 after controlling for gender and level of
polypharmacy, OR 0.39 (95% CI 0.39 to 0.4).
Conclusions: Accounting for the marked increase in
polypharmacy, prescribing quality appears to have
improved with a reduction in the odds of having PIP
from 1997 to 2012. With growing numbers of people
taking multiple regular medicines, strategies to
address the related challenges of polypharmacy and
PIP are needed.
INTRODUCTION
The volume of medicines being prescribed
has risen in recent years.1 Despite this, con-
cerns have been raised that patients who are
eligible for evidence-based treatments are not
receiving them.2 Set against the background
of a rising burden of illness, some commenta-
tors have called for the use of more medicines
to alleviate pain and disability, prolong life
and prevent avoidable disease.2 3
In contrast, there is increasing concern
about overdiagnosis and overtreatment, par-
ticularly in elderly patients.4 5 There has
been a proliferation of clinical guidelines
focused on single conditions, which fail to
account for the growing cohort of patients
with multimorbidity.6 7 In older people,
there has been particular focus on polyphar-
macy, commonly deﬁned as the use of ﬁve or
more regular medicines. Although polyphar-
macy has been used as a crude marker of
prescribing quality, it can in many cases, such
as multimorbidity, be entirely appropriate.8 9
A clearer indicator of medicines safety and
prescribing quality is potentially inappropri-
ate prescribing (PIP), the use of a medicine
such that the harms outweigh the beneﬁts,10
as exposure to PIP medicines is associated
with adverse outcomes, including adverse
drug events and hospitalisations.10 11
Strengths and limitations of this study
▪ This is a large-scale study of pharmacy claims
data assessing trends in prescribing across a
long time period.
▪ Individual-level data on dispensed medicines
allow for the relationship between two common
prescribing issues in older people to be exam-
ined over time.
▪ Results relating to those under the age of
70 years may be less generalisable due to over-
representation of individuals with lower socio-
economic status.
▪ The potentially inappropriate prescribing criteria
used were published in 2008, so prescribers
may not have had knowledge of inappropriate-
ness of some medicines in the early study years.
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These two issues are inter-related, as polypharmacy is
the single biggest predictor of being prescribed a PIP
medicine.10 12 Although it appears that polypharmacy
and PIP have become more widespread in recent years,
the relationship between these issues over time is not
clearly understood.
In this study, we analyse pharmacy claims data over a
15 year time period from 1997 to 2012 in primary care
in Ireland to examine: (1) the change in prescribing
patterns and rates of polypharmacy (being prescribed
≥5 regular medicines) in all individuals, (2) the change
in prevalence of PIP in individuals aged ≥65 years and
(3) the relationship between PIP and polypharmacy in
these older individuals.
METHODS
Study design and setting
A repeated cross-sectional study was conducted using
patient-level dispensing data from an administrative
pharmacy claims database in the years 1997, 2002, 2007
and 2012, a period of 15 years. Data were included for
all people eligible for the General Medical Services
(GMS) scheme in the study years in the former Eastern
Health Board (EHB) region of Ireland, where 29.1% of
the national population resided in 2012.13
The GMS scheme is a means-tested form of public
health cover in Ireland providing free health services,
including most prescribed medicines, to people based
on income and age, although a monthly copayment per
prescription item was introduced in 2010. As of 2012,
40.1% of the general Irish population and 96.5% of
those over 70 years were covered by the scheme.13 14
From 2002 to 2008, all people aged 70 years or over
were automatically eligible for the scheme and since
January 2009, a higher income threshold was applied to
this age group compared to the general population.
The Health Services Executive-Primary Care
Reimbursement Service (HSE-PCRS) database used for
this study contains dispensing records of medicines pre-
scribed to patients in primary care by their general prac-
titioners. For this analysis, medicines were classiﬁed into
drug classes based on the ﬁrst ﬁve characters of their
WHO Anatomical Therapeutic Chemical (ATC) code
and only dispensing data relating to individual patients
were included. Speciﬁc ethical approval for this study
was not required as all data were fully anonymised.
Data analysis
Regular medicines and polypharmacy in the total population
The number of regular medicines (dispensed in at least
three consecutive months) per person during each study
year was analysed to determine the distribution of indivi-
duals by age group and number of regular medicines
(category aggregated at 15 or more medicines). The
most prevalent medicines (grouped by level 5 ATC
code) were also examined by determining the number
of individuals to whom each medicine was regularly
dispensed. For the years 1997 to 2007, this was directly
standardised by age group and gender to the 2012 GMS
population of the EHB region to account for changing
demographics and to allow comparison across years.
The prevalence of polypharmacy (being dispensed ﬁve
or more regular medicines in the study year) and exces-
sive polypharmacy (conventionally deﬁned as 10 or more
regular medicines) was calculated.15 Negative binomial
regression was used to quantify the change in the rate of
these outcomes associated with study year (using 1997 as
the reference year), controlling for age group and
gender. Interaction terms between these independent
variables were included if they provided a statistically sig-
niﬁcant improvement to model ﬁt. Incident rate ratios
(IRR) with 95% CIs are presented. Negative binomial
models were used over Poisson models due to over-
dispersion in the rates of polypharmacy.16
PIP in older individuals
Prescribing inappropriateness was assessed in individuals
aged ≥65 years using a subset of criteria from the
Screening Tool for Older Persons’ Prescription
(STOPP). This explicit measure of PIP was applied as it
was developed for use in older European populations
and includes more medicines than the Beers criteria
which are commonly prescribed in the study setting.17 18
Analysis was restricted to older individuals, as explicit
measures of PIP such as STOPP have not been validated
in younger age groups. Thirty of sixty-ﬁve criteria (see
online supplementary appendix S1) were applicable to
the information in the HSE-PCRS administrative data set
and lack of detailed clinical information precluded
application of the remaining criteria, consistent with
other studies applying STOPP to pharmacy claims
data.19 PIP prevalence was assessed by the percentage of
individuals with any PIP criteria. Prevalence for each
individual STOPP criteria was also determined to
examine the most common forms of PIP over the study
period.
The relationship between PIP and polypharmacy in older
individuals
Unadjusted logistic regression was performed to assess
the change in odds of having any PIP over the study
years and ORs with 95% CIs are presented. The relation-
ship between PIP prevalence (dependent variable) and
rates of polypharmacy across years was explored using
multivariate logistic regression. Covariates included in
the model were year (1997 as the reference), level of
polypharmacy (0–4 medicines (reference), 5–9 medi-
cines, and ≥10 medicines) and gender. A sensitivity ana-
lysis was performed post hoc to assess the impact of
excluding the STOPP criterion with the largest contribu-
tion to PIP in 2012, long-term use of proton pump inhi-
bitors (PPIs) at maximal dose, from the analysis.
Statistical analyses were performed using SAS 9.2 (SAS
Institute Inc., Cary, North Carolina, USA). Signiﬁcance
at p<0.05 was assumed.
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RESULTS
Regular medicines and polypharmacy in the total
population
The number of individuals included in this study in
1997, 2002, 2007 and 2012 were 338 025, 344 270,
373 007 and 539 752, respectively. Figure 1 shows the
proportion of each age group by the number of regular
medicines prescribed for each study year. There is a
clear increase in the proportion of individuals on higher
numbers of medicines, particularly in the two oldest age
groups.
The rates of prescription per 1000 GMS-eligible
patients of the 15 most common regular medicines
in 2012 compared to the age-standardised and
sex-standardised rates in previous years are shown in
ﬁgure 2. Statins were prescribed to the highest number
of individuals, and like antiplatelet drugs and PPIs, there
have been large increases in the numbers of people on
these medicines over the study period. Several other car-
diovascular drugs were among the most commonly pre-
scribed medicines. Benzodiazepine anxiolytics were one
of the few medicines not to show a year on year increase
over this time. Prescribing of related medicines, such as
selective serotonin reuptake inhibitors and non-
benzodiazepine (Z-drug) hypnotics, did show an upward
trend during the study period.
Of those aged 45–64 years, the percentage with poly-
pharmacy (on ﬁve or more regular medicines) increased
from 8.3% to 30.2% over the study period, and for those
aged ≥65 years it rose from 17.8% to 60.4%. A similar
trend was observed for excessive polypharmacy (on 10
or more regular medicines), with the prevalence
increasing during this time from 0.8% to 8.3% in those
aged 45–64 years and from 1.5% to 21.9% in people
≥65 years.
In the negative binomial regression analysis (table 1),
the adjusted IRR for polypharmacy in 2012 compared to
1997 is 4.16 (95% CI 3.23 to 5.36). In the model for
excessive polypharmacy, the adjusted IRR for 2012 com-
pared to 1997 is 10.53 (95% CI 8.58 to 12.91). For both
of these outcomes, there was a trend of increasing
adjusted IRR for polypharmacy across the study years
controlling for age and gender.
PIP in older individuals
There were 78 489 individuals aged 65 or above
included in 1997, 121 726 in 2002, 129 162 in 2007 and
133 884 in 2012. The prevalence of PIP in these indivi-
duals in 1997 using 30 STOPP criteria was 32.6%. This
fell to 28.6% in 2002; however, the percentage with PIP
increased in the more recent study years to 32.8% in
2007 and 37.3% in 2012 (see online supplementary
appendix S2).
A number of PIP criteria decreased in prevalence
across the study period, with the largest reductions
in prescribing of high doses of aspirin and digoxin
(ﬁgure 3). Although the rates of long-term use of benzo-
diazepines and non-steroidal anti-inﬂammatory drugs
(NSAIDs) have ﬂuctuated across the study period, the
prevalence of these criteria has remained high (>3%).
An increase in duplication of drug classes was observed,
in particular duplicate opioids. The largest increase in
prevalence of a criterion was PPIs at maximum dosage
for >8 weeks, which rose from 0.8% in 1997 to 23.6% in
Figure 1 Percentage of eligible population by number of regular medicines for the years 1997–2012.
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2012. This is the major contributor to the overall PIP
prevalence and a sensitivity analysis excluding this criter-
ion showed a consistent decrease in overall PIP preva-
lence (32.3%, 24.9%, 22.6% and 20.8% from 1997 to
2012).
The relationship between PIP and polypharmacy in older
individuals
The trend of PIP prevalence across the study years was
conﬁrmed in the univariate logistic regression where the
odds of having any PIP were lower in 2002 compared to
1997 and then rose in 2007 and 2012 compared to 1997
(table 2). After adjusting for gender and level of poly-
pharmacy in the multivariable logistic regression, a
trend of reducing odds of having a PIP across the study
years is observed. The adjusted OR for having a PIP for
polypharmacy compared to no polypharmacy is 6.83
(95% CI 6.73 to 6.93) and for excessive polypharmacy
(≥10 medicines) compared to no polypharmacy is 22.05
(95% CI 21.57 to 22.54). In the sensitivity analysis using
prevalence of any PIP excluding long-term maximal
dose PPI as the outcome, an even greater reduction in
the odds of having a PIP was observed over the study
period (adjusted OR for PIP in 2012 is 0.2 (95% CI 0.19
to 0.2) compared to in 1997).
DISCUSSION
Principal findings
Between 1997 and 2012, there was a substantial increase
in the prescribing of regular medicines, particularly in
older adults, with a fourfold increase in polypharmacy
and a 10-fold increase in excessive polypharmacy, inde-
pendent of age and gender. PIP prevalence also rose,
largely due to increasing maximal dose PPI use that
masked the reduction across most of the other PIP med-
icines. After controlling for changes in polypharmacy
over time, there has been a reduction in the odds of
having any PIP in recent years.
Findings in the context of the literature
Other studies have also reported an increase over time
in drugs prescribed to individual patients, though
they examined different time frames to the present
study.20–22 This has implications for healthcare provision;
for example, the number of ofﬁce-based visits by elderly
patients with polypharmacy quadrupled between 1990
and 2000 in the USA.23 Higher rates of excessive poly-
pharmacy were observed in this study, possibly due to
the proportion of individuals with lower incomes being
included, as lower socioeconomic status and deprivation
can be associated with polypharmacy, multimorbidity
and lower quality prescribing.21 24 25
Much research on trends in PIP found decreasing
prevalence over time,26–28 and the number of regular
medicines or polypharmacy was consistently reported as
being the strongest predictor of PIP.26 27 In relation to
speciﬁc PIP medicines, signiﬁcant quantities of maximal
dose PPIs continue to be prescribed. This is despite the
potential cost-savings of optimising use being raised in
the USA and Ireland ($47.1 billion and €40.5 million
Figure 2 Standardised rates of prescribing of most common regular medicines in all individuals in 2012. Abbreviations: SSRIs,
selective serotonin reuptake inhibitors; PPIs, proton pump inhibitors.
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per annum)19 29 and concerns regarding the clinical
implications of such PPI overprescribing.30 Long-term
NSAIDs and benzodiazepine use in older people,
deﬁned as inappropriate in the STOPP and Beers cri-
teria,18 is also of concern as such prescribing remains
prevalent across countries and is associated with high-
risk adverse events in vulnerable elderly patients.31 32
Implications for policy and practice
The growth in prescribing in recent years, particularly in
middle and older age groups, means more individuals
have polypharmacy than ever before (see online supple-
mentary appendix 2), suggesting that a threshold of ﬁve
or more medicines may no longer speciﬁcally identify
higher risk patients.33 Polypharmacy was estimated to
cost US health plans at least $50 billion annually in 2002
and continued growth since then is likely to have had a
major impact on pharmaceutical expenditure.34
A number of factors may be contributing to increasing
polypharmacy. The growing prevalence of multimorbid-
ity twinned with the use of single condition-focused
treatment guidelines are likely to have contributed to
the higher rates of polypharmacy.6 More patient-centred
care may help address this conﬂict between evidence-
based medicine and effective multimorbidity manage-
ment.35 There may also be a growing acceptance that
the medicalisation of older age is of beneﬁt to patients.3
Prescribing indications for common medicines such as
Table 1 Adjusted negative binomial regression models for polypharmacy and excessive polypharmacy in all individuals
Polypharmacy* Excessive polypharmacy†
Adjusted IRR‡ 95% CI Adjusted IRR§ 95% CI
Year
1997 (reference) 1 – 1 –
2002 2.18 (1.69 to 2.82) 3.53 (2.86 to 4.36)
2007 3.49 (2.71 to 4.49) 8.07 (6.55 to 9.93)
2012 4.16 (3.23 to 5.36) 10.53 (8.58 to 12.91)
*Polypharmacy defined as 5 or more regular medicines.
†Excessive polypharmacy defined as 10 or more regular medicines.
‡Adjusted for age group and gender (both significant, p<0.01).
§Adjusted for age group, gender and age group-gender interaction (all significant, p<0.01).
IRR, incident rate ratio.
Figure 3 Prevalence of most common types of PIP in individuals aged ≥65 years. Abbreviations: H2, histamine-2 receptor;
TCA, tricyclic antidepressant; CCB, calcium channel blocker; PPI, proton pump inhibitor; COPD, chronic obstructive pulmonary
disease; NSAID, non-steroidal anti-inflammatory drug; T2DM, type 2 diabetes mellitus.
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statins and PPIs have expanded since they were ﬁrst mar-
keted and the use of such agents has become increas-
ingly widespread.36 37 It appears that the mass
prescription of preventive medicines is becoming more
acceptable, as illustrated by the increasing number of
people on statins.38 A prescription no longer signals
treatment of a sick patient and this has implications for
what polypharmacy indicates in modern healthcare.38
The relationship between polypharmacy and use of PIP
drugs is complex. While polypharmacy and excessive
polypharmacy are strongly associated with PIP, the
picture that emerges in our setting is that when
the number of prescribed medicines is accounted for, the
chance of being prescribed a PIP medicine has decreased
over time (table 3). These analyses illustrate the complex,
competing factors inﬂuencing prescribing. On the one
hand, there is increasing medicines use being driven by
clinical practice guidelines and other forms of external
evidence that mandate prescribing. On the other hand,
there is an awareness of iatrogenic harm and that the use
of PIP medicines needs to be justiﬁed and, if possible,
limited. Interventions to improve the appropriate use of
polypharmacy have been effective in reducing inappro-
priate prescribing, but the clinical signiﬁcance of such
improvements is unclear.39 Deprescribing of medications
among older people with multimorbidity and polyphar-
macy to reduce the drug burden may also yield patient
beneﬁts; however, the evidence base for this approach
needs to be further developed.40
Study strengths and weaknesses
The large study population and length of the follow-up
period means these results are more likely to be general-
isable and less likely to be due to short-term ﬂuctuations
in prescribing practice. The study utilises primary care
dispensing data from a pharmacy claims database, which
allows for medicines use of individuals to be explored as
opposed to population-level drugs consumption.
Dispensing data sources, unlike prescribing databases,
can account for primary non-adherence to prescriptions
and so is more likely to reﬂect actual medicines use by
patients; however, we do not know if patients actually
take the medicines dispensed or if they are taking
over-the-counter medicines. No clinical or diagnostic
information is available in this data source. Therefore,
only a subset of STOPP criteria could be applied, pos-
sibly underestimating the actual prevalence of PIP in
this population. There could also be clinical justiﬁcation
for some instances of PIP, which cannot be identiﬁed
without a full patient medical record. For example, long-
term PPIs at high doses may be appropriate in managing
Barrett’s oesophagus.
A further limitation of this study is that only people
eligible for the means-tested GMS scheme in the EHB
region could be included. Deprived individuals may
therefore be over-represented, as are females and the
younger and older populations who are possibly more
likely to have polypharmacy.21 However, for much of the
study period, all over 70s were eligible for the GMS
scheme and so, for the older population, the ﬁndings
are likely to be largely representative and not biased by
socioeconomic status. Some forms of prescribing
included may not have been considered potentially
inappropriate from evidence available before the publi-
cation of the STOPP criteria in 2008. The reduction in
prevalence of such criteria may illustrate evidence being
incorporated into practice as it became available.
Conclusions
This study shows a marked increase in prescribed medi-
cines over a relatively short time and increasing poly-
pharmacy is the main driver of exposure to PIP.
Prescribing of certain PIP medicines has declined,
which could indicate an increasing recognition among
prescribers that these medicines may be potentially
inappropriate. Reassuringly, after controlling for increas-
ing polypharmacy, the odds of older individuals being
exposed to PIP have reduced with time; given the
increased medicines burden, clinicians seem to be pre-
scribing more appropriately.
In the future, two related issues need to be addressed.
First, quality improvement strategies and interventions
should be considered to improve prescribing appropri-
ateness further, particularly for prevalent PIP medicines
such as benzodiazepines, NSAIDs and PPIs. Second,
interventions for patients need to make clear the trade-
off between taking more medicines to prevent disease or
minimise disability and the potential for iatrogenic harm
from PIP drugs that occur more commonly with
polypharmacy.
Table 2 Unadjusted and adjusted logistic regression models for having any PIP criteria in individuals aged ≥65 years
Any PIP (unadjusted) Any PIP (adjusted)
OR 95% CI Adjusted OR* 95% CI
Year
1997 (reference) 1 – 1 –
2002 0.83 (0.81 to 0.84) 0.53 (0.52 to 0.54)
2007 1.01 (0.99 to 1.03) 0.38 (0.38 to 0.39)
2012 1.23 (1.21 to 1.25) 0.39 (0.39 to 0.40)
*Adjusted for level of polypharmacy (0–4 medicines (reference), 5–9 medicines, ≥10 medicines) and gender (all significant, p<0.01).
PIP, potentially inappropriate prescribing.
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